Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1031 of 6351
-
Engineered immune cells take aim at tough blood cancers
Disease control CompletedThe primary purpose of this study is to test whether CD22-CAR T cells can be successfully made from immune cells collected from adults with relapsed/refractory B-cell malignancies (leukemia and lymphoma).
Phase 1 • Sponsor: Matthew Frank • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New immunotherapy combo shows promise for tough lung cancer
Disease control CompletedThis is a randomized, double-blind, multicenter, phase III clinical study to compare the clinical efficacy and safety of HLX10+ Chemotherapy vs placebo+Chemotherapy in Previously Untreated Patients with Extensive Stage Small Cell Lung Cancer. Eligible subjects in this study will…
Phase 3 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Talking it out: could Village-Led chats curb youth suicide?
Prevention CompletedThis intervention study measures the outcomes of the PC CARES (Promoting Community Conversations about Research to End Suicide) project implemented in remote rural Alaskan villages. Researchers worked with local service providers and other partners to recruit facilitators who wer…
Sponsor: University of Michigan • Aim: Prevention
Last updated Aug 21, 2026 00:00 UTC
-
Killer virus turned against childhood brain cancer
Disease control Recruiting nowThis study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell ki…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New drug cocktail aims to control rare blood cancer without chemo
Disease control OngoingIn Waldenström macroglobulinemia (WM) conventional chemotherapy induces only low complete remission (CR) rates and responses of short duration compared to other indolent lymphomas. Thus innovative approaches are needed which combine excellent activity and tolerability in patients…
Phase 2 • Sponsor: Christian Buske • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New drug combo shows promise for chinese men with advanced prostate cancer
Disease control OngoingThe purpose of this study was to evaluate the efficacy and safety of enzalutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT in Chinese subjects with metastatic hormone sensitive prostate cancer (mHSPC). The study was conducted in two phases: Double-Blind tre…
Phase 3 • Sponsor: Astellas (Beijing) Pharmaceutical R&D Co., Ltd. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Aggressive chemo cocktail aims to wipe out rectal cancer before surgery
Disease control OngoingPathologic complete response rate
Phase 2 • Sponsor: CCTU • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Simple blood test could spare prostate cancer patients from repeat biopsies
Diagnosis Recruiting nowA multi-center, prospective active surveillance registry trial assessing the performance of a non-invasive blood test for indolent prostate cancer disease management.
Sponsor: Immunis.AI • Aim: Diagnosis
Last updated Jun 27, 2026 12:03 UTC
-
New drug aims to shrink GI cancers before surgery
Disease control OngoingThis is a phase II, open-label, prospective single-centered study. Subjects who meet the inclusion/exclusion criteria will be allocated to appropriate cohorts: 1) gastric cancer, 2) esophageal cancer and 3) hepatocellular carcinoma. Each cancer cohort group will be treated with t…
Phase 2 • Sponsor: Asan Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New combo therapy shows promise for aggressive breast cancer
Disease control OngoingThe human epidermal growth factor receptor 2 (HER2) regulates cell growth and survival. Approximately 15-20% of all breast cancers are HER2-positive, which are an aggressive and fast-growing subtype of breast cancer. This study will evaluate a new treatment using a potent Poly po…
Phase 1/2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Immunotherapy boosts standard chemoradiation in HPV+ throat cancer trial
Disease control CompletedThe purpose of this study is to find out if the addition of nivolumab can improve 2 year progression free survival (PFS) as compared to standard of care of fractionated radiation therapy (RT) and carboplatin/paclitaxel in subjects with high risk HPV-related squamous cell carcinom…
Phase 2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New hope for kids with chronic migraines: drug trial shows promise
Symptom relief CompletedThis study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to \<12 years) and adolescents (12 to \<18 years) with chronic migraine. The study hypothesis is that in pediatric participants with chronic migraine, the combined erenumab dose gro…
Phase 3 • Sponsor: Amgen • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC
-
Could a blood vessel drug boost exercise capacity in cystic fibrosis?
Disease control CompletedExercise intolerance is an understudied phenomenon in people with CF. The investigators hypothesized that vascular dysfunction plays a significant role, and can be partially reversed by administration of the phosphodiesterase type 5 (PDE5) inhibitor, sildenafil.
Phase 2/3 • Sponsor: National Jewish Health • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Could a common CF drug help those with rare mutations?
Disease control CompletedThis clinical study will enroll 42 participants without the F508del mutation, carrying partial function or N1303K mutations not approved for Trikafta, and who are not expected to be approved for CFTR modulator treatment in the immediate future. Each participant will be given Trik…
Phase 2 • Sponsor: Emory University • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Could a common antiviral help fight brain cancer?
Disease control OngoingThis study is a multicenter randomized double-blinded controlled phase 2 study evaluating the efficacy and safety of the anti-CMV drug valganciclovir vs placebo as add-on therapy in patients with glioblastoma. Valganciclovir is approved for treatment of cytomegalovirus (CMV) infe…
Phase 2 • Sponsor: Cecilia Soderberg-Naucler • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New cocktail of drugs takes on tough lung cancers in Never-Smokers
Disease control OngoingWhile cigarette smoking remains the primary cause of most lung cancer cases, lung carcinoma in never smokers account for nearly 20 percent of cases. Never smokers with lung cancer typically present with different molecular profiles from that of smokers, which results in prognosti…
Phase 2 • Sponsor: Fox Chase Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Could a gentle brain zap help stroke survivors find their words again?
Symptom relief OngoingThe purpose this study is to test the utility of pairing external neuromodulation with behavioral language treatment to boost therapy outcomes and to investigate the mechanisms associated with recovery. Because all PWA have word retrieval deficits, this project will test if great…
Sponsor: University of Arkansas • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
New rabies shot shows promise in preventing deadly infection after bites
Prevention CompletedThis is a Phase 2b, double blinded, randomized study of SYN023 compared to HyperRab® (a licensed Rabies immune globulin from human sources, HRIG) for the prevention of rabies as part of post-exposure prophylaxis (PEP). The trial will enroll sequentially two different risk substra…
Phase 2 • Sponsor: Synermore Biologics Co., Ltd. • Aim: Prevention
Last updated Jul 01, 2026 00:00 UTC
-
Heart attack drug shows promise in reducing inflammation
Disease control CompletedVascular and myocardial inflammation are significantly increased in Acute Coronary Syndrome (ACS) patients, are closely correlated to LDL-C levels, and are associated with these adverse consequences in the post-ACS patient population. Serum proprotein convertase subtilisin/kerin …
Phase 2 • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Can a weekly infusion slow the toll of a rare genetic disease?
Disease control OngoingMulticenter, open-label, single-group, designed to evaluate the long term efficacy and safety of study drug for the treatment of the MPS II.
Phase 2/3 • Sponsor: JCR Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC